Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Scientific Correspondence
  • Published:

Effects of progesterone or neuroactive steroid?

Abstract

Smithet al.1 reported some interesting results about the effects of progesterone treatment and withdrawal on the gene encoding the GABAAreceptor α4 subunit, a constituent of receptors for the neurotransmitter GABA (γ-aminobutyric acid). However, we disagree with their conclusion that the effects of progesterone withdrawal are mediated by reduced levels in the brain of the GABAAreceptor active neurosteroid 3α-OH-5α-pregnan-20-one (3α,5α-THP, or allopregnanalone). The ability of indomethacin to reverse the effects of progesterone was interpreted as evidence that the effects of progesterone were mediated by 3α,5α-THP. Smith et al.1 did not provide direct evidence that levels of 3α,5α-THP were reduced by indomethacin (which reversed the effects of progesterone), or that progesterone levels were not altered by indomethacin. In some cases, indomethacin can increase progesterone levels directly2, which may explain why indomethacin can reverse the effects of progesterone withdrawal.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Indomethacin increases stress-induced 3α,5α-THP levels in rat cerebral cortex.

References

  1. Smith, S. S. et al. Nature 392, 926–930 (1998).

    Article  ADS  CAS  Google Scholar 

  2. Bjurulf, E., Selstam, G. & Olofsson, J. . J. Reprod. Fertil. 102, 139–145 (1994).

    Google Scholar 

  3. Uzunov, D. P., Cooper, T. B., Costa, E. & Guidotti, A. Proc. Natl Acad. Sci. USA 93, 12599–12604 (1996).

    Google Scholar 

  4. Devaud, L. L., Purdy, R. H., Finn, D. A. & Morrow, A. L. J. Pharmacol. Exp. Ther. 278, 510–517 (1996).

    Google Scholar 

  5. Devaud, L. L., Purdy, R. H. & Morrow, A. L. Alcohol. Clin. Exp. Res. 19, 350–355 (1995).

    Google Scholar 

  6. Devaud, L. L., Fritschy, J. M., Sieghart, W. & Morrow, A. L. J. Neurochem. 69, 126–130 (1997).

    Google Scholar 

  7. Costa, A. M., Spence, K. T., Smith, S. S. & ffrench-Mullen, J. M. H. J. Neurophysiol. 74, 464–469 (1995).

    Google Scholar 

  8. Smith, S. S. et al. J. Neurosci. 18, 5275–5284 (1998).

    Google Scholar 

  9. Penning, T. M., Sharp, R. B. & Krieger, N. R. J. Biol. Chem. 260, 15266–15272 (1985).

    Google Scholar 

  10. Bernardi, F. et al. Eur. J. Endocrinol. 138, 316–321 (1998).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morrow, A., VanDoren, M. & Devaud, L. Effects of progesterone or neuroactive steroid?. Nature 395, 652 (1998). https://doi.org/10.1038/27106

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/27106

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing